ESTIMATED
11/09/2023
11/09/2023
Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 0 | $1.57 | $1.57 | $1.57 |
Q2 2024 | 0 | $1.34 | $1.34 | $1.34 |
Q3 2024 | 0 | $1.54 | $1.54 | $1.54 |
NeuBase Therapeutics, Inc. last posted its earnings results on Thursday, November 9th, 2023. The company reported $-0.95 earnings per share for the quarter, topping analysts' consensus estimates of $-1.82 by $0.87. The company had revenue of 0 for the quarter and had revenue of 0 for the year. NeuBase Therapeutics, Inc. has generated $-21 earnings per share over the last year ($-21.08 diluted earnings per share) and currently has a price-to-earnings ratio of -0.07. NeuBase Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, August 12th, 2024 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue | 11/09/2023 | Q4 2023 | -$1.82 | -$0.66 | 1.16 | $0 | $0 | 08/14/2023 | Q3 2023 | -$1.80 | -$2.04 | -0.24 | $0 | 05/11/2023 | Q2 2023 | -$2.00 | -$2.40 | -0.4 | $0 | 02/14/2023 | Q1 2023 | -$2.20 | -$3.04 | -0.84 | $0 | 12/21/2022 | Q4 2022 | -$5.40 | -$4.67 | 0.73 | $0 | 08/11/2022 | Q3 2022 | -$6.00 | -$5.35 | 0.65 | $0 | 05/12/2022 | Q2 2022 | -$5.20 | -$6.07 | -0.87 | $0 | 02/10/2022 | Q1 2022 | -$4.72 | $0 | 12/23/2021 | Q4 2021 | -$5.40 | -$4.38 | 1.02 | $0 | 08/13/2021 | Q3 2021 | -$5.76 | $0 | 05/13/2021 | Q2 2021 | -$4.76 | $0 | 02/11/2021 | Q1 2021 | -$4.80 | -$3.51 | 1.29 | $0 | 12/23/2020 | Q4 2020 | -$4.00 | -$4.06 | -0.06 | $0 | 08/13/2020 | Q3 2020 | -$4.80 | -$3.59 | 1.21 | $0 | 05/14/2020 | Q2 2020 | -$4.40 | -$5.13 | -0.73 | $0 | 03/26/2020 | Q1 2020 | -$7.20 | -$5.28 | 1.92 | $0 | 01/10/2020 | Q4 2019 | -$27.85 | $0 | 08/14/2019 | Q3 2019 | -$8.01 | $0 | 05/15/2019 | Q2 2019 | -$8.08 | $0 | 02/14/2019 | Q1 2019 | -$6.35 | $0 |
---|
A. NeuBase Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, August 12th, 2024 based off last year's report dates.
A. In the previous quarter, NeuBase Therapeutics, Inc. (NASDAQ:NBSE) reported $-0.95 earnings per share (EPS) to beat the analysts' consensus estimate of $-1.82 by $0.87.
A. The conference call for NeuBase Therapeutics, Inc.'s latest earnings report can be listened to online.
A. The conference call transcript for NeuBase Therapeutics, Inc.'s latest earnings report can be read online.
A. NeuBase Therapeutics, Inc. (NASDAQ:NBSE) has a recorded net income of $0. NeuBase Therapeutics, Inc. has generated $-21.08 earnings per share over the last four quarters.
A. NeuBase Therapeutics, Inc. (NASDAQ:NBSE) has a price-to-earnings ratio of -0.07 and price/earnings-to-growth ratio is 0.01.